Regulatory
Merck KGAA MS Drug on the Fast Track
FDA to give priority review to new tablets for the treatment of multiple sclerosis—a potential boon for a disease in need of innovation and reigniting competition with Novartis.
Advertisement:
Camgemini
Are You Really Closing the Loop?
There is a considerable advantage to being one of the first companies in pharma to successfully close the loop and pave the way to a new commercial model that puts the customer first. However, implementing comprehensive, closed-loop marketing has proven difficult for many in our industry. Capgemini Consulting examines the functional implications for implementing closed-loop marketing across the commercial organization and the hurdles to overcome to fully close the loop.
 Click here
|
Sales Management
GSK Rethinks Rep Compensation
Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented.
Study
Future of Personalized Medicine
Survey concludes physicians optimistic on future, so long as financial incentives remain strong to encourage collaboration between all parties involved.
Europe
Resisting the Anticompetitive Crusade
It's been another rocky few weeks for pharma in Europe—particularly for big brand-name companies. But necessity is proving the mother of invention, says Pharm Exec's Brussels correspondent, Reflector.
New & Noteworthy
Managing the Middle
Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.
|
